Qualitative assessment of EOB-GD-DTPA and Gd-BT-DO3A MR contrast studies in HCC patients and colorectal liver metastases

Infectious Agents and Cancer - Tập 14 - Trang 1-9 - 2019
Vincenza Granata1, Roberta Fusco1, Francesca Maio2, Antonio Avallone3, Guglielmo Nasti3, Raffaele Palaia4, Vittorio Albino4, Roberto Grassi5, Francesco Izzo4, Antonella Petrillo1
1Division of Radiology, ISTITUTO NAZIONALE TUMORI – IRCCS - FONDAZIONE G. PASCALE, NAPOLI, ITALIA, Naples, Italy
2Division of Radiology, Università degli Studi di Napoli Federico II, Naples, Italy
3Division of Abdominal Oncology, ISTITUTO NAZIONALE TUMORI – IRCCS - FONDAZIONE G. PASCALE, NAPOLI, ITALIA, Naples, Italy
4Division of Abdominal Surgical Oncology, Hepatobiliary, ISTITUTO NAZIONALE TUMORI – IRCCS - FONDAZIONE G. PASCALE, NAPOLI, ITALIA, Naples, Italy
5Division of Radiology, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy

Tóm tắt

To compare liver-specific EOB-GD-DTPA and liver-non-specific Gd-BT-DO3A MR, in hepatocellular carcinoma (HCC) and liver colorectal metastases. Seventy HCC patients with 158 nodules and 90 colorectal liver metastases (mCRC) with 370 lesions were included in the retrospective analysis. HCC patients underwent MR at 0 time (MR0), after 3 (MR3) and 6 months (MR6) using two different CM; 69 mCRC patients underwent MR with Gd-EOB-BTPA and 21 mCRC patients with Gd-BT-DO3A. We evaluated arterial phase hyperenhancement, lesion-to-liver contrast during portal phase, hepatobiliary phase parenchymal hyperenhancement. In HCC patients arterial phase hyperenhancement degree was statistically higher (p = 0.03) with Gd-BT-DO3A (mean 4) than GD-EOB-DTPA (mean 2.6), while we found no significant statistical differences among mean (2.6) values at MR0 and MR6 using GD-EOB-DTPA. For all 209 patients underwent Gd-EOB-DTPA, we found that lesion-to-liver contrast during portal phase mean value was 4 while for patients underwent MR with Gd-BT-DO3A was 3 (p = 0.04). For HCC hepatobiliary phase parenchymal hyperenhancement mean value was 2.4. For mCRC patients: among 63 patients underwent previous chemotherapy hepatobiliary phase parenchymal hyperenhancement mean value was 3.1 while for 6 patients no underwent previous chemotherapy was 4 (p = 0.05). Gd-EOB-DTPA should be chosen in pre surgical setting in patients with colorectal liver metastases.

Tài liệu tham khảo

Van Beers BE, Pastor CM, Hussain HK. Primovist, Eovist: what to expect? J Hepatol. 2012;57(2):421–9.

Granata V, Fusco R, Avallone A, Filice F, Tatangelo F, Piccirillo M, Grassi R, Izzo F, Petrillo A. Critical analysis of the major and ancillary imaging features of LI-RADS on 127 proven HCCs evaluated with functional and morphological MRI: lights and shadows. Oncotarget. 2017;8(31):51224–37.

Granata V, Fusco R, Avallone A, Catalano O, Filice F, Leongito M, Palaia R, Izzo F, Petrillo A. Major and ancillary magnetic resonance features of LI-RADS to assess HCC: an overview and update. Infect Agent Cancer. 2017;12:23.

Granata V, Cascella M, Fusco R, dell’Aprovitola N, Catalano O, Filice S, Schiavone V, Izzo F, Cuomo A, Petrillo A. Immediate Adverse Reactions to Gadolinium-Based MR Contrast Media: A Retrospective Analysis on 10,608 Examinations. Biomed Res Int. 2016;2016:3918292.

Granata V, Catalano O, Fusco R, Tatangelo F, Rega D, Nasti G, Avallone A, Piccirillo M, Izzo F, Petrillo A. The target sign in colorectal liver metastases: an atypical Gd-EOB-DTPA "uptake" on the hepatobiliary phase of MR imaging. Abdom Imaging. 2015;40(7):2364–71.

Goodwin MD, Dobson JE, Sirlin CB, Lim BG, Stella DL. Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents. Radiographics. 2011;31:1547–68.

Davenport MS, Viglianti BL, Al-Hawary MM, Caoili EM, Kaza RK, Liu PS, Maturen KE, Chenevert TL, Hussain HK. Comparison of acute transient dyspnea after intravenous adminis- tration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality. Radiology. 2013;266:452–61.

Pietryga JA, Burke LM, Marin D, Jaffe TA, Bashir MR. Respiratory motion artifact affecting hepatic arterial phase imaging with gadoxetate disodium: examination recovery with a multiple arterial phase acquisition. Radiology. 2014;271:426–34.

Davenport MS, Bashir MR, Pietryga JA, Weber JT, Khalatbari S, Hussain HK. Dose-toxicity relationship of gadoxetate disodium and transient severe respiratory motion artifact. AJR Am J Roentgenol. 2014;203:796–802.

Akai H, Yasaka K, Nojima M, Kunimatsu A, Inoue Y, Abe O, Ohtomo K, Kiryu S. Gadoxetate disodium-induced tachypnoea and the effect of dilution method: a proof-of-concept study in mice. Eur Radiol. 2017 Sep;11.

Davenport MS, Viglianti BL, Al-Hawary MM, Caoili EM, Kaza RK, Liu PS, Maturen KE, Chenevert TL, Hussain HK. Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality. Radiology. 2013;266(2):452–61.

Bashir MR, Castelli P, Davenport MS, Larson D, Marin D, Hussain HK, Jaffe TA. Respiratory motion artifact affecting hepatic arterial phase MR imaging with gadoxetate disodium is more common in patients with a prior episode of arterial phase motion associated with gadoxetate disodium. Radiology. 2015;274:141–8.

Pietryga JA, Burke LM, Marin D, Jaffe TA, Bashir MR. Respiratory motion artifact affect- ing hepatic arterial phase imaging with gadoxetate disodium: examination recovery with a multiple arterial phase acquisition. Radiology. 2014;271:426–34.

Davenport MS, Caoili EM, Kaza RK, Hussain HK. Matched within-patient cohort study of transient arterial phase respiratory motion-related artifact in MR imaging of the liver: gadoxetate disodium versus gadobenate dimeglumine. Radiology. 2014;272:123–31.

Yoo JL, Lee CH, Park YS, Kim JW, Lee J, Kim KA, Seol HY, Park CM. The short breath-hold technique, controlled aliasing in parallel imaging results in higher acceleration, can be the first step to overcoming a degraded hepatic arterial phase in liver magnetic resonance imaging: a prospective randomized control study. Investig Radiol. 2016;51(7):440–6.

Schalkx HJ, van Stralen M, Coenegrachts K, van den Bosch MA, van Kessel CS, van Hillegersberg R, van Erpecum KJ, Verkooijen HM, Pluim JP, Veldhuis WB, van Leeuwen MS. Liver perfusion in dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI): comparison of enhancement in Gd-BT-DO3A and Gd-EOB DTPA in normal liver parenchyma. Eur Radiol. 2014;24(9):2146–56.

Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60.

Saito K, Kotake F, Ito N, et al. Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci. 2005;4:1–9.

Vogl TJ, Kummel S, Hammerstingl R, et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology. 1996;200:59–67.

Feuerlein S, Gupta RT, Boll DT, Merkle EM. Hepatocellular MR contrast agents: enhancement characteristics of liver parenchyma and portal vein after administration of gadoxetic acid in comparison to gadobenate dimeglumine. Eur J Radiol. 2012;81(9):2037–41.

Cruite I, Schroeder M, Merkle EM, Sirlin CB. Gadoxetate disodium-enhanced MRI of the liver: part 2, protocol optimization and lesion appearance in the cirrhotic liver. AJR Am J Roentgenol. 2010;195(1):29–41.

Campos JT, Sirlin CB, Choi JY. Focal hepatic lesions in Gd- EOB-DTPA enhanced MRI: the atlas. Insights Imaging. 2012;3(5):451–74.

Schalkx HJ, van Stralen M, Coenegrachts K, van den Bosch MA, van Kessel CS, van Hillegersberg R, van Erpecum KJ, Verkooijen HM, Pluim JP, Veldhuis WB, van Leeuwen MS. Liver perfusion in dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI): comparison of enhancement in Gd-BT-DO3A and Gd-EOB-DTPA in normal liver parenchyma. Eur Radiol. 2014 Sep;24(9):2146–56.

Reimer P, Rummeny EJ, Daldrup HE, Hesse T, Balzer T, Tombach B, Peters PE. Enhancement characteristics of liver metastases, hepato- cellular carcinomas, and hemangiomas with Gd-EOB-DTPA: prelim- inary results with dynamic MR imaging. Eur Radiol. 1997;7(2):275–80.

Dahlqvist Leinhard O, Dahlstrom N, Kihlberg J, Sandström P, Brismar TB, Smedby O, Lundberg P. Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: a pilot study. Eur Radiol. 2012;22(3):642–53.

Frydrychowicz A, Nagle SK, D'Souza SL, Vigen KK, Reeder SB. Optimized high-resolution contrast-enhanced hepatobiliary imaging at 3 tesla: a cross-over comparison of gadobenate dimeglumine and gadoxetic acid. J Magn Reson Imaging. 2011;34(3):585–94.

Filippone A, Blakeborough A, Breuer J, Grazioli L, Gschwend S, Hammerstingl R, Heinz-Peer G, Kittner T, Laghi A, Leen E, Lencioni R, Lucidarme O, Remplik P, Robinson PJ, Ruehm SG, Schaefer F, Stoupis C, Tombach B, Valette PJ, Zech CJ, Huppertz A. Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine. J Magn Reson Imaging. 2010;31(2):356–64.

Granata V, Fusco R, Avallone A, Catalano O, Piccirillo M, Palaia R, Nasti G, Petrillo A, Izzo F. A radiologist's point of view in the presurgical and intraoperative setting of colorectal liver metastases. Future Oncol. 2018. https://doi.org/10.2217/fon-2018-0080.

Tsuda N, Okada M, Murakami T. New proposal for the staging of nonalcoholic steatohepatitis: evaluation of liver fibrosis on Gd-EOB-DTPA-enhanced MRI. Eur J Radiol. 2010;73:137–42.

Planchamp C, Pastor CM, Balant L, Becker CD, Terrier F, Gex-Fabry M. Quantification of Gd-BOPTA uptake and biliary excretion from dynamic magnetic resonance imaging in rat livers: model validation with 153Gd-BOPTA. Investig Radiol. 2005;40:705–14.

Tajima T, Takao H, Akai H, Imamura H, Watanabe Y, Shibahara J, Kokudo N, Akahane M, Ohtomo K. Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging. J Comput Assist Tomogr. 2010;34:362–6.

Motosugi U, Ichikawa T, Sou H, Sano K, Tominaga L, Kitamura T, Araki T. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EO B-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging. 2009;30:1042–6.

Tamada T, Ito K, Higaki A, Yoshida K, Kanki A, Sato T, Higashi H, Sone T. Gd-EOB-DTPA-enhanced MR imaging: evaluation of hepatic enhancement effects in normal and cirrhotic livers. Eur J Radiol. 2011;80:311–6.

Motosugi U, Ichikawa T, Oguri M, Sano K, Sou H, Muhi A, Matsuda M, Fujii H, Enomoto N, Araki T. Staging liver fibrosis by using liver-enhancement ratio of gadoxetic acid-enhanced MR imaging: comparison with aspartate aminotransferase-to-platelet ratio index. Magn Reson Imaging. 2011;29:1047–52.

Utsunomiya T, Shimada M, Hanaoka J, Kanamoto M, Ikemoto T, Morine Y, Imura S, Harada M. Possible utility of MRI using Gd-EOB-DTPA for estimating liver functional reserve. J Gastroenterol. 2012;47:470–6.

Nishie A, Ushijima Y, Tajima T, Asayama Y, Ishigami K, Kakihara D, Nakayama T, Takayama Y, Okamoto D, Abe K, Obara M, Yoshimitsu K, Honda H. Quantitative analysis of liver function using superparamagnetic iron oxide- and Gd-EOB-DTPA-enhanced MRI: comparison with technetium-99m galactosyl serum albumin scintigraphy. Eur J Radiol. 2012;81:1100–4.

Watanabe H, Kanematsu M, Goshima S, Kondo H, Onozuka M, Moriyama N, Bae KT. Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging-preliminary observations. Radiology. 2011;259:142–50.

Katsube T, Okada M, Kumano S, Imaoka I, Kagawa Y, Hori M, Ishii K, Tanigawa N, Imai Y, Kudo M, Murakami T. Estimation of liver function using T1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging. Investig Radiol. 2011;46:277–83.

Galia M, Agnello F, Sparacia G, Matranga D, Albano D, Midiri M, Lagalla R. Evolution of indeterminate hepatocellular nodules at Gd-EOB-DPTA-enhanced MRI in cirrhotic patients. Radiol Med. 2018 Jul;123(7):489–97.

Granata V, Fusco R, Filice S, Incollingo P, Belli A, Izzo F, Petrillo A. Comment on "State of the art in magnetic resonance imaging of hepatocellular carcinoma": the role of DWI. Radiol Oncol. 2019 Jul 13.

Calistri L, Castellani A, Matteuzzi B et al. Focal Liver Lesions Classifications and Characterization. What Value do DWI and ADC have? J Comput Assist Tomogr 40:701–8.

Izzo F, Granata V, Grassi R, Fusco R, Palaia R, Delrio P, Carrafiello G, Azoulay D, Petrillo A, Curley SA. Radiofrequency Ablation and Microwave Ablation in Liver Tumors: An Update. Oncologist. 2019 Jun 19. pii:theoncologist.2018–0337.

Granata V, Fusco R, Setola SV, Picone C, Vallone P, Belli A, Incollingo P, Albino V, Tatangelo F, Izzo F, Petrillo A. Microvascular invasion and grading in hepatocellular carcinoma: correlation with major and ancillary features according to LIRADS. Abdom Radiol (NY). 2019;44(8):2788–800.

Granata V, Fusco R, Filice S, Catalano O, Piccirillo M, Palaia R, Izzo F, Petrillo A. The current role and future prospectives of functional parameters by diffusion weighted imaging in the assessment of histologic grade of HCC. Infect Agent Cancer. 2018;13:23.

Granata V, Md FR, Catalano O, Filice S, Avallone A, Piccirillo M, Leongito M, Palaia R, Grassi R, Izzo F, Petrillo A. Uncommon neoplasms of the biliary tract: radiological findings. Br J Radiol. 2017;90(1078):20160561.

Granata V, Fusco R, Catalano O, Avallone A, Palaia R, Botti G, Tatangelo F, Granata F, Cascella M, Izzo F, Petrillo A. Diagnostic accuracy of magnetic resonance, computed tomography and contrast enhanced ultrasound in radiological multimodality assessment of peribiliary liver metastases. PLoS One. 2017;12(6):e0179951.

Granata V, Fusco R, Catalano O, Avallone A, Leongito M, Izzo F, Petrillo A. Peribiliary liver metastases MR findings. Med Oncol. 2017;34(7):124.

Thông tin
Thông tin xuất bản

Infectious Agents and Cancer

Tập 14

1-9

Thông tin tác giả